Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | EBP | Q15125 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3926676 | 0.88 | L3MBTL1 (0.75) | L3MBTL1SMN1; SMN2MAPK1CYP1A2MAPT | |
| SCHEMBL493879 | 0.86 | L3MBTL1 (0.79) | L3MBTL1SMN1; SMN2MAPK1CYP1A2MAPT | |
| Hydrochloric Acid SCHEMBL4710262 | 0.86 | L3MBTL1 (0.72) | L3MBTL1SMN1; SMN2MAPK1CYP1A2MAPT | |
| Hydrochloric Acid SCHEMBL2710255 | 0.84 | L3MBTL1 (0.76) | L3MBTL1SMN1; SMN2MAPK1CYP1A2MAPT | |
| SCHEMBL3321939 | 0.84 | L3MBTL1 (0.68) | L3MBTL1SMN1; SMN2MAPK1CYP1A2MAPT | |
| SCHEMBL2877981 | 0.82 | L3MBTL1 (0.72) | L3MBTL1SMN1; SMN2MAPK1CYP1A2MAPT | |
| SCHEMBL5507736 | 0.80 | L3MBTL1 (0.69) | L3MBTL1SMN1; SMN2MAPK1CYP1A2MAPT | |
| SCHEMBL30701387 | 0.80 | L3MBTL1 (0.69) | L3MBTL1SMN1; SMN2MAPK1CYP1A2MAPT | |
| SCHEMBL5500455 | 0.80 | L3MBTL1 (0.69) | L3MBTL1SMN1; SMN2MAPK1CYP1A2MAPT | |
| SCHEMBL10624598 | 0.80 | L3MBTL1 (0.69) | L3MBTL1SMN1; SMN2MAPK1CYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917015-A1 | NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | claimed |
| WO-2007019884-A1 | NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | claimed |
| US-20050256154-A1 | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides | LUK KIN-CHUN | 2005-11-17 | — | — | US | claimed |
| EP-1917015-A1 | NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007019884-A1 | NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20050256154-A1 | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides | LUK KIN-CHUN | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256154-A1 | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides | FGFR3, FGFR4, FGFR1 | HTR1A 2177/4885ADRA2A 1197/4885ADRA2C 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.